NewLink Genetics Corporation - Product Pipeline Review - H2 2011

Global Markets Direct, November 2011, Pages: 47

NewLink Genetics Corporation – Product Pipeline Review – H2 2011

Summary

Global Market Direct’s pharmaceuticals report, “NewLink Genetics Corporation - Product Pipeline Review - H2 2011” provides data on the NewLink Genetics Corporation’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, NewLink Genetics Corporation’s corporate website, SEC filings, investor presentations and featured press releases, both from NewLink Genetics Corporation and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- NewLink Genetics Corporation - Brief NewLink Genetics Corporation overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of NewLink Genetics Corporation human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of NewLink Genetics Corporation with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the NewLink Genetics Corporation’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate NewLink Genetics Corporation’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of NewLink Genetics Corporation in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the NewLink Genetics Corporation’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with NewLink Genetics Corporation.
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of NewLink Genetics Corporation and identify potential opportunities in those areas.

Keywords

Current R&D Portfolio of NewLink Genetics Corporation; NewLink Genetics Corporation - Key Therapeutics; NewLink Genetics Corporation - Pipeline Overview and Promising Molecules; NewLink Genetics Corporation - News; NewLink Genetics Corporation - Latest Updates; NewLink Genetics Corporation - Pipeline; NewLink Genetics Corporation - Discontinued/Dormant Projects

List of Tables
List of Figures
NewLink Genetics Corporation Snapshot
NewLink Genetics Corporation Overview
Key Information
Key Facts
NewLink Genetics Corporation – Research and Development Overview
Key Therapeutic Areas
NewLink Genetics Corporation – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Pipeline Products – Combination Treatment Modalities
NewLink Genetics Corporation – Pipeline Products Glance
NewLink Genetics Corporation – Late Stage Pipeline
Phase III Products/Combination Treatment Modalities
NewLink Genetics Corporation Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
NewLink Genetics Corporation – Drug Profiles
D-1MT
Product Description
Mechanism of Action
R&D Progress
D-1MT + Ad-p53
Product Description
Mechanism of Action
R&D Progress
D-1MT + Taxotere
Product Description
Mechanism of Action
R&D Progress
HyperAcute Lung Cancer Vaccine
Product Description
Mechanism of Action
R&D Progress
HyperAcute-Melanoma Vaccine
Product Description
Mechanism of Action
R&D Progress
HyperAcute-Pancreas Immunotherapy
Product Description
Mechanism of Action
R&D Progress
NewLink Genetics Corporation – Pipeline Analysis
NewLink Genetics Corporation – Pipeline Products by Therapeutic Class
NewLink Genetics Corporation - Pipeline Products By Target
NewLink Genetics Corporation – Pipeline Products by Route of Administration
NewLink Genetics Corporation – Pipeline Products by Molecule Type
NewLink Genetics Corporation – Recent Pipeline Updates
NewLink Genetics Corporation - Dormant Projects
NewLink Genetics Corporation - Discontinued Pipeline Products
Discontinued Pipeline Product Profiles
HyperAcute-Breast Cancer Vaccine
NewLink Genetics Corporation – Locations And Subsidiaries
Head Office
Recent Developments
May 31, 2011: NewLink Genetics To Present Data On HyperAcute Melanoma Immunotherapy At American Society Of Clinical Oncology Annual Meeting
May 31, 2011: NewLink Genetics To Present Data On HyperAcute Prostate Immunotherapy At American Society Of Clinical Oncology Annual Meeting
May 27, 2010: NewLink Initiates Pivotal Phase III Clinical Trial Of HyperAcute-Pancreas Immunotherapy For Resected Pancreatic Cancer
Jan 21, 2011: NewLink Genetics To Present Phase II Data Of HyperAcute Pancreas Immunotherapy At ASCO 2011 Gastrointestinal Cancers Symposium
May 20, 2010: NewLink Genetics To Present Phase II Data Of HyperAcute-Pancreas Immunotherapy For Resected Pancreatic Cancer
Apr 19, 2010: NewLink Genetics Presents Positive Phase I/II Data On HyperAcute-Lung Cancer Immunotherapy
Jun 07, 2010: NewLink Genetics Reports Positive Data From Phase II Trial Of HyperAcute-Pancreas Cancer Immunotherapy
Jun 06, 2010: NewLink Genetics' HyperAcute Immunotherapy Phase II Study Shows Promise In Disease Free And Overall Survival For Resectable Pancreatic Cancer
Apr 01, 2011: NewLink Genetics To Present Phase II Data Of HyperAcute Lung Immunotherapy At AACR 102nd Annual Meeting 2011
Financial Deals Landscape
NewLink Genetics Corporation, Deals Summary
NewLink Genetics Corporation, Pharmaceuticals & Healthcare, Deal Details
Venture Financing
NewLink Genetics Secures $30 Million In Series C Financing
NewLink Genetics Raises $7.5 Million In Series D Round Of Financing
NewLink Genetics Raises $17 Million In Series C Financing
Licensing Agreements
LIMR Enters Into Worldwide Licensing Agreement With NewLink Genetics
Equity Offering
NewLink Genetics Completes Initial Public Offering Of Common Stock For $43.4 Million
NewLink Genetics Completes Private Placement Of $0.25 Million
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
NewLink Genetics Corporation – Pipeline by Therapy Area and Indication, H2 2011
NewLink Genetics Corporation – Pipeline by Stage of Development, H2 2011
NewLink Genetics Corporation – Monotherapy Products in Pipeline, H2 2011
NewLink Genetics Corporation – Combination Treatment Modalities in Pipeline, H2 2011
NewLink Genetics Corporation – Phase III, H2 2011
NewLink Genetics Corporation - Phase II, H2 2011
NewLink Genetics Corporation - Phase I, H2 2011
NewLink Genetics Corporation - Pipeline By Therapeutic Class, H2 2011
NewLink Genetics Corporation - Pipeline By Target, H2 2011
NewLink Genetics Corporation – Pipeline By Route of Administration, H2 2011
NewLink Genetics Corporation – Pipeline By Molecule Type, H2 2011
NewLink Genetics Corporation – Recent Pipeline Updates, H2 2011
NewLink Genetics Corporation - Dormant Developmental Projects, 2010
NewLink Genetics Corporation - Discontinued Pipeline Products, 2010
NewLink Genetics Corporation, Deals Summary
NewLink Genetics Secures $30 Million In Series C Financing
NewLink Genetics Raises $7.5 Million In Series D Round Of Financing
NewLink Genetics Raises $17 Million In Series C Financing
LIMR Enters Into Worldwide Licensing Agreement With NewLink Genetics
NewLink Genetics Completes Initial Public Offering Of Common Stock For $43.4 Million
NewLink Genetics Completes Private Placement Of $0.25 Million

List of Figures
NewLink Genetics Corporation – Pipeline by Therapy Area and Indication, H2 2011
NewLink Genetics Corporation – Pipeline by Stage of Development, H2 2011
NewLink Genetics Corporation – Monotherapy Products in Pipeline, H2 2011
NewLink Genetics Corporation – Combination Treatment Modalities in Pipeline, H2 2011
NewLink Genetics Corporation – Pipeline By Therapeutic Class, H2 2011
NewLink Genetics Corporation - Pipeline By Target, H2 2011
NewLink Genetics Corporation – Pipeline By Route of Administration, H2 2011
NewLink Genetics Corporation – Pipeline By Molecule Type, H2 2011

Customers who bought this item also bought

• Top Five Global Software Companies: Performance, Strategies and Competitive Analysis
• Scientific Games Corporation - Company Analysis
• EarthLink: Strategic Corporate Assessment - Strategy, SWOT Analysis and 5-year Financial Insights with In-depth Company Profile
• eBay - Strong Execution
• Apple, Inc. - Strategies, Financial Outlook and Competitive Benchmark Analysis
• Hewlett-Packard Company - Strategies, Financial Outlook and Competitive Benchmark Analysis
• ModusLink Global Solutions Inc,(MLNK) Profile and Financials, plus E-Commerce & Internet Industry Trends Analysis, Operating Ratio and Financial Averages
• Net Savings Link, Inc.,(NSAV) Profile and Financials, plus E-Commerce & Internet Industry Trends Analysis, Operating Ratio and Financial Averages
• CenturyLink Inc,(CTL) Profile and Financials, plus E-Commerce & Internet Industry Trends Analysis, Operating Ratio and Financial Averages
• EarthLink Inc,(ELNK) Profile and Financials, plus E-Commerce & Internet Industry Trends Analysis, Operating Ratio and Financial Averages